Earnings Feed
Start Free
Home/Filings/4/0000950170-24-132929
4//SEC Filing

Prudo-Chlebosz Raymond 4

Accession 0000950170-24-132929

CIK 0001541157other
View on SEC.govCompany Profile

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 5:48 PM ET

Size

9.2 KB

Accession

0000950170-24-132929

Insider Transaction Report

Form 4
Period: 2024-12-02
Akari Therapeutics PlcAKTX
Prudo-Chlebosz Raymond
Director
Transactions
  • Award

    Warrants (Right to Buy)

    2024-12-02$0.00/sh+419,286,000$503,143→ 419,286,000 total
    Exercise: $0.00From: 2024-12-02Exp: 2027-12-02→ Ordinary Shares, par value $0.0001 per share (419,286,000 underlying)
  • Award

    Ordinary Shares, par value $0.0001 per share

    2024-12-02$0.00/sh+419,286,000$503,143→ 4,077,124,600 total
Holdings

  • Ordinary Shares, par value $0.0001 per share

    (indirect: RPC Pharma Limited)
    800,766,600

  • Ordinary Shares, par value $0.0001 per share

    (indirect: By Trust)
    38,709,600
Footnotes (3)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.
  • [F2]On December 2, 2024, the Reporting Person acquired 419,286,000 Ordinary Shares and accompanying warrants to purchase up to 419,286,000 Ordinary Shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement dated as of November 13, 2024. The combined purchase price was $0.001193 per Ordinary Share and accompanying warrant.
  • [F3]The warrants have an exercise price of $0.001130 per Ordinary Share.

Documents

1 file

Issuer

Akari Therapeutics Plc

CIK 0001541157

→
Entity typeother

Related Parties

1
  • filerCIK 0001653262

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 5:48 PM ET
Size
9.2 KB
View on SEC.gov